209 related articles for article (PubMed ID: 33050484)
1. From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?
Luvero D; Lopez S; Bogani G; Raspagliesi F; Angioli R
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33050484
[TBL] [Abstract][Full Text] [Related]
2. The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC.
Yusupov A; Popovsky D; Mahmood L; Kim AS; Akman AE; Yuan H
Am J Stem Cells; 2019; 8(3):52-64. PubMed ID: 31976155
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.
Luvero D; Plotti F; Lopez S; Scaletta G; Capriglione S; Montera R; Antonelli G; Ciuffreda S; Carassiti R; Oliveti A; Angioli R
Med Oncol; 2017 Jun; 34(6):115. PubMed ID: 28477178
[TBL] [Abstract][Full Text] [Related]
4. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.
Wang R; Pan W; Jin L; Huang W; Li Y; Wu D; Gao C; Ma D; Liao S
Cancer Lett; 2020 Feb; 471():88-102. PubMed ID: 31812696
[TBL] [Abstract][Full Text] [Related]
6. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
7. Current status of human papillomavirus vaccines.
Kim KS; Park SA; Ko KN; Yi S; Cho YJ
Clin Exp Vaccine Res; 2014 Jul; 3(2):168-75. PubMed ID: 25003090
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
9. Ten years of HPV vaccines: State of art and controversies.
Angioli R; Lopez S; Aloisi A; Terranova C; De Cicco C; Scaletta G; Capriglione S; Miranda A; Luvero D; Ricciardi R; Montera R; Plotti F
Crit Rev Oncol Hematol; 2016 Jun; 102():65-72. PubMed ID: 27066937
[TBL] [Abstract][Full Text] [Related]
10. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
Joura EA; Pils S
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
[TBL] [Abstract][Full Text] [Related]
11. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
12. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
13. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
14. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
15. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.
Toh ZQ; Kosasih J; Russell FM; Garland SM; Mulholland EK; Licciardi PV
Infect Drug Resist; 2019; 12():1951-1967. PubMed ID: 31308715
[TBL] [Abstract][Full Text] [Related]
17. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
18. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
Chatterjee A
Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
[TBL] [Abstract][Full Text] [Related]
19. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
20. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
